C2N Diagnostics has secured $1,500,000 in investment capital from investors. The company, driven by its vision of "Clarity Through Innovation™," focuses on therapeutic discovery and diagnostic solutions for human neurological disorders, aiming to prevent or stop disease progression and enhance patient care through advanced brain health monitoring.
A cornerstone of C2N Diagnostics' offerings is the PrecivityAD™ blood test. This mass spectrometry-based test, performed in the company's CLIA-certified laboratory, measures multiple analytes in blood, including Aβ42, Aβ40, and apolipoprotein E isoforms. The PrecivityAD™ test serves as an important new tool for physicians to aid in the evaluation process by predicting brain amyloid plaques, as determined by PET scan results. It is crucial to note that while highly informative, the test by itself does not diagnose Alzheimer’s disease, which remains a clinical diagnosis made by a healthcare provider. The test received a Breakthrough Device Designation from the U.S. Food and Drug Administration in 2019 and has also achieved the CE Mark from the European Union, underscoring its relevance in the diagnostic landscape.
This new investment capital underscores confidence in C2N Diagnostics’ specialized approach to advancing diagnostics for neurological conditions. The company plans to strategically deploy the $1,500,000 to support continued growth initiatives. This includes further development and commercialization efforts for its diagnostic platforms, aiming to broaden accessibility and impact.
With this secured funding, C2N Diagnostics is positioned to strengthen its efforts in bringing accurate, widely accessible, and cost-effective blood tests to the clinic. The company remains committed to improving patient care and brain health monitoring by expanding its diagnostic capabilities and reach within the neurological diagnostics market.
